Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Tuesday July 9

Poster Exhibitions

TuPeB4654 Paraclinic markers and oral lesions in HIV/AIDS
Mexican children undergoing highly active
antiretroviral therapy
L Gaitan, M Cashat, J Morales, R Fragoso,
V Cuairan, L Calderon (Mexico)
TuPeB4655 HIV treatment for children: applying the 2002
WHO interim ARV treatment guidelines for
resource poor settings
B Vareldzis', S Qazi1, C Giaquinto2
(lSwitzerland; 2Italy)
TuPeB4656 Changes in viral load, CD4 counts and
antiretroviral therapy over time in a pediatric
population in Ontario, Canada
SE Read C Major, L Samson, J Beyene,
C Swantee, M Fearon, U Allen (Canada)
TuPeB4657 A new generation at risk: Youth & HIV
J Grosz, D C Harvey (United States)
TuPeB4658 Impact of HAART on the survival and disease
progression in HIV-1 infected children
JI M Sanchez-Granados M P Carrefho,
M I Gonzalez-Tome, P Ferrando, J Ruiz-Contreras,
J T Ramos (Spain)
TuPeB4659 Access to ART and appropriate management
provides a fresh lease of life to paediatric HIV
patients in India
S Chanqedia, I S Gilada (India)
TuPeB466o Access to HAART in M6decins Sans Frontihres
programmes
Mddecins Sans Frontihres and Epicentre
(Belgium)
TuPeB4661 When to start HAART: evidence to support
initiating therapy at CD4+ lymphocyte counts 350
cells/uL
J E Kaplan D Hanson, D Cohn, J Karon, S Buskin,
M Thompson, P Fleming, M Dworkin
(United States)
TuPeB4662 Effect of baseline CD4 cell count on
immunological response to antiretroviral therapy
in therapy-naive HIV-i-infected individuals:
analysis of the St Mary's H IV clinical database
LA Paddam J N Weber, A ] Frater, D T Dunn,
S J Pocock (United Kingdom)
TuPeB4663 Prediction of residual time to AIDS and death
based on marker and cofactor values
R B Geskus, FA Miedema, J Goudsmit, P Reiss,
H Schuitemaker, R A Coutinho (The Netherlands)
TuPeB4664 When to start? The effect of adherence on
disease progression after the initiation of
combination antiretroviral therapy
K L Peterson, W J Burman L W Yun, D L Cohn,
A ] Davidson (United States)
TuPeB4665 Increase in bodily pain among other markers of
quality of life, in HIV-infected patients during the
first year of HAART
S Duran, B Spire, C Katlama, P Carrieri, Vjournot,
A Sobel, I M Besnier, I P Moatti, C Leport (France)
TuPeB4666 Factors predicting uptake of HAART at varying
CD4 levels
A S Walker on behalf of the CASCADE
Collaboration (United Kingdom)
TuPeB4667 Short-term immunological response in pretreated and naive subjects initiating HAART at
different times following seroconversion
CA Sabin, on behalf of CASCADE Collaboration
(United Kingdom)

TuPeB4668 Construction and validation of a prognostic
model for progression to AIDS or death in drugnafve patients starting potent antiretroviral
therapy ART Cohort Collaboration
M May, jA C Sterne', D Costagliola2, P Pezzott3,
B Ledergerber4, F de Wolf, I D Lundgren6,
A C Justice7, V Miller", G Chene2, FDabis2,
R S Hogg9, C Sabin', M JGil/9, B Salzberger,
M Egger' (United Kingdom; 2 France; 3Italy;
4Switzerland; 5The Netherlands; 6Denmark;
7United States; 8Germany; 9Canada)
TuPeB4669 Simple predictive markers of death in HIV-1
infected Ethiopians and their relevance in the
decision of initiation of antiretroviral therapy
(ART)
Y Mekonnen', N Dukers2, E Sanders', W DorigoZetsma, D Wolday1, R Geskus2, R Coutinho2,
A Fontanet2 CEthiopia; 2The Netherlands)
TuPeB467o Effect of time since seroconversion on response
to HAART in naive patients with a known date of
seroconversion
C EA Lindenburgq, M W Langendam', J Hubert2,
L Meyer2, FMiedema, RA Coutinhol, Fde Wolfp
(The Netherlands; 2France)
TuPeB4671 Pre-HAART delayed-type hypersensitivity testing
(DTH) independently predicts death and incident
AIDS-defining illness (ADI) in HIV-1 infected
women after HAART initiation
K Anastos Q Shi, A French, R Greenblatt,
R Delapenha, J DeHovitz, A Levine, D Hoover
(United States)
TuPeB4672 The impact of physician experience, Adherence,
and baseline CD4 Cell count on rates of disease
progression among HIV-1 infected patients
initiating triple drug therapy
E Wood, R S Hogg, B Yip, M V O'Shaughnessy,
IS Montaner (Canada)
TuPeB4673 In routine practice, the durability of first line
HAART is better for NNRTI than PI-based
regimens, regardless baseline HIV status
A Moreno M J Perez-Elfas, J L Casado, A Antela,
C Quereda, M Uriarte, E Bermddez, E Navas,
F Dronda, S Moreno (Spain)
TuPeB4674 Is a CD4 count above 200 cells/mcil a safe cut-off
value to start antiretroviral therapy (ARVT)?
M JPerez-Elfas A Moreno, S Moreno, J L Casado,
A Antela, F Dronda, C Quereda, E Navas,
L Moreno (Spain)
TuPeB4675 HIV-1 DNA and RNA kinetics in primary HIV
infection
F Lillo, MA Grasso, B Capiluppi, G Tambussi
(Italy)
TuPeC4676 Demographic and clinical profile of 328 HIV
seropositives of Kerala, South India:
a preliminary report
R Rajendran, B Devasia (India)
TuPeC4677 A study of STD profile and HIV prevalence in 5oo
cases of vaginal discharge in Civil Hospital, B. J.
Medical College, Ahmedebad, 1999-2001
R CR Raval, A SM Mantri, NM B Bhavasr,
FE B Billimoria (India)
TuPeC4678 Epidemiological aspects of Morbus HIV in the
Region Nis-Serbia
B Tiodorovic, B Petrovic, G Tasic, I Tiodorovic
(Yugoslavia)
TuPeC4679 Correlation of Mortality with HIV/AIDS in
Transkei, South Africa

B L Meel (South Africa)

Tuesday

XIV International AIDS Conference BARCELONA - JULY 7-12

103